Avandia risks back in the headlines

It's time to add insult to injury in Avandia-land. It wasn't enough that a new study in the Journal of the American Medical Association find that the diabetes drug doubles the risk of heart failure and boosted heart-attack risk by 42 percent. Another JAMA study showed that Actos, a rival drug, actually lowered the risk of heart attacks, strokes and death (though risk of heart failure did rise).

GlaxoSmithKline defended Avandia, saying that the new studies are "flawed" and that they offer "no new information." The company says the drug is still safe and effective when used appropriately. Still, inspired by all the bad publicity, patients have switched drugs and docs have put the brakes on new prescriptions--meaning, of course, that sales have plunged.

Could further regulatory action be far behind? An FDA advisory panel voted in July to leave Avandia on the market; since then, the drug was slapped with a "black box" warning. Now, a JAMA editorial claims that, had the FDA known now what it did when Avandia came up for approval, the drug would never have hit the market. The authors of these new studies say it should be withdrawn. No question: The pressure on the FDA to act again has intensified. All the agency will say now is that it's continuing to monitor the situation.

- see Glaxo's defense of Avandia
- here's the article from The New York Times

Related Articles:
FDA adds to drumbeat of bad news for Avandia. Report
What to do with Avandia sales force? Report
Expert committee says Avandia should stay. Report
FDA expert wants Avandia withdrawn. Report
Docs shunning Avandia in wake of safety study. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.